Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/21/24
End: 04/30/29
Due: 04/30/30
Phase: N/A
Priority: Normal
Start: 05/25/21
End: 01/10/25
Due: 01/10/26
Phase: N/A
Priority: Normal
Start: 09/28/22
End: 09/30/27
Due: 09/30/28
Phase: N/A
Priority: Normal
Start: 02/28/23
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis | NCT06450886 | Abcuro, Inc. | user2@example.com | None | 2024-10-21 | 2029-04-30 | 2030-04-30 | - | - | 2025-07-14 |
| A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) | NCT04659031 | Abcuro, Inc. | user2@example.com | None | 2021-05-25 | 2025-01-10 | 2026-01-10 | - | - | 2025-07-14 |
| ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | NCT05532722 | Abcuro, Inc. | user2@example.com | None | 2022-09-28 | 2027-09-30 | 2028-09-30 | - | - | 2025-07-14 |
| A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | NCT05721573 | Abcuro, Inc. | user2@example.com | None | 2023-02-28 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |